IP Library Granted Patent US 8,067,196
Granted Patent B2
US 8,067,196 · App. 10/473,180 · Granted Nov 29, 2011

6-O sulfated polysaccharides and methods of preparation thereof

Assignee: Massachusetts Institute of Technology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,067,196
App. No.
10/473,180
Granted
Nov 29, 2011
Kind
B2
Abstract

Disclosed are methods of 6-O-sulfating glucosaminyl N-acetylglucosamine residues (GlcNAc) in a polysaccharide preparation and methods of converting anticoagulant-inactive heparan sulfate to anticoagulant-active heparan sulfate and substantially pure polysaccharide preparations may by such methods. Also disclosed is a mutant CHO cell which hyper-produces anticoagulant-active heparan sulfate. Methods for elucidating the sequence of activity of enzymes in a biosynthetic pathway are provided.

Claims (34)

1. An in vitro method of transferring a sulfate on to the 6-O position of a GlcNAc sugar residue in a polysaccharide preparation, the method comprising the steps of

(a) providing a polysaccharide preparation having GlcNAc sugar residues, and

(b) contacting the polysaccharide preparation provided in (a) with glucosaminyl-6-O-sulfotransferase (6-OST) protein in the presence of a sulfate donor whereby the 6-OST protein adds a sulfate to the 6-O-position of a GlcNAc sugar residue; and

wherein said polysaccharide preparation comprises heparin.

2. The method of claim 1 , whereby the polysaccharide preparation comprises glucuronic acid (GlcUA) residues.

3. The method of claim 1 , whereby the polysaccharide preparation includes GlcUA-GlcNAc 2 sugar residues.

4. The method of claim 1 , whereby the polysaccharide preparation includes disaccharides elected from the consisting of GlcUA/IdoUA-GlcNS, IdoUA2S-GlcNS, and GlcUA-GlcNS3S.

5. The method of claim 1 , whereby the polysaccharide preparation includes GlcNAc/NS6S-GlcUA-GlcNS3 S±6S-IdoUA2S-GlcNS6S.

6. The method of claim 1 , whereby the polysaccharide preparation includes GlcNAc/NS-GlcUA-GlcNS3 S±6S-IdoUA2S-GlcNS6S.

7. The method of claim 1 , whereby the polysaccharide preparation includes GlcNAc/NS6S-GlcUA-GlcNS3S±-IdoUA2S-GlcNS6S.

8. The method of claim 1 , whereby the polysaccharide preparation includes GlcNAc/NS6S-GlcUA-GlcNS3S±6S-IdoUA2S-GlcNS.

9. The method of claim 1 , whereby the 6-OST protein is a recombinant protein.

10. The method of claim 9 , whereby the 6-OST protein is a human recombinant protein.

11. The method of claim 9 , whereby the recombinant protein is produced in a expression system selected from the group consisting of baculovirus cells, yeast cells, bacterial cells, and mammalian cells.

12. The method as in claim 1 , whereby the sulfate donor is 3′-phospho-adenosine 5′-phosphosulfate (PAPS).

13. The method of claim 1 , whereby the 6-O-sulfation is performed in a reaction mixture comprising at least one chloride salt and wherein the pH is between 6.5 and 7.5.

14. The method of claim 1 , whereby the polysaccharide preparation is contacted with 6-OST protein in the presence of a sulfate donor for at least 20 minutes.

15. An in vitro method of enriching the portion of anticoagulant active Heparin Sulfate (HS act ) present in a polysaccharide preparation comprising:

(a) providing a d-O-sulfated polysaccharide preparation; and

(b) contacting the preparation with 6-OST protein in the presence of a sulfate donor under conditions, which permit the 6-OST protein to add a sulfate to the 6-O-position of a GlcNAc sugar residue, wherein step (b) occurs concurrent with or subsequent to step (a).

16. The method of claim 15 , whereby the 3-O-sulfated polysaccharide preparation is made in a CHO cell that expresses 3-OST-1 protein.

17. The method of claim 16 , whereby the 3-O-sulfate polysaccharide preparation is prepared by contacting anticoagulant inactive Heparin Sulfate (HSin act ) with 3-OST-1 protein.

18. The method of claim 15 , whereby the polysaccharide preparation comprises heparan.

19. The method of claim 15 , whereby the percentage of HS act present in the polysaccharide preparation following step (b) is greater than 70%.

20. The method of claim 15 , whereby the percentage of HS act present in the polysaccharide preparation following step (b) is greater than 50%.

21. The method of claim 15 , whereby the polysaccharide preparation comprise N-acetylglucosamine (GlcNAc) and glucuronic acid (GlcUA) residues.

22. The method as in claim 15 , whereby the polysaccharide preparation includes sugar residues selected from the group consisting of GlcUA/IdoUA-GlcNS, GlcUA-GlcNAc, IdoUA2S-GlcNS, and GlcUA-GlcNS3S.

23. The method of claim 15 , whereby the sulfate donor comprises PAPS.

24. The method of claim 15 , whereby the 6-O-sulfation is performed in a reaction mixture comprising at least one chloride salt at a pH of about 6.5-7.5.

25. The method as in any one of claim 24 , whereby the 6-OST protein comprises a polypeptide selected from the group consisting of

(a) human 6-OST-1 (SEQ ID NO. 3);

(b) human 6-OST-2A (SEQ ID NO. 4);

(c) human 6-OST-2B (SEQ ID NO. 5);

(d) human 6-OST-3 (SEQ ID NO. 6).

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 25, 2012
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029034/0816 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2004
From: ROSENBERG, ROBERT D.; ZHANG, LIJUAN; BEELER, DAVID J.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 015081/0910 →
Continuity (3)
Provisional Application 60279523 · Mar 28, 2001
Provisional Application 60316289 · Aug 30, 2001
Related Publication 20040191870A1 · Sep 30, 2004